A Randomized Phase III Trial to Determine whether Conjugated Pneumococcal Vaccine Can Improve the Immune Responsiveness and Lead to Fewer Infections Compared to Polysaccharide Pneumococcal Vaccine in Patients with Untreated Chronic Lymphocytic Leukemia.

Trial Profile

A Randomized Phase III Trial to Determine whether Conjugated Pneumococcal Vaccine Can Improve the Immune Responsiveness and Lead to Fewer Infections Compared to Polysaccharide Pneumococcal Vaccine in Patients with Untreated Chronic Lymphocytic Leukemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 25 Jun 2017 Primary endpoint has been met. (Immune response to Pneumovax compared to immune response to Prevenar) as per result presented at the 22nd Congress of the European Haematology Association
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
    • 05 Apr 2017 Based on the correspondance with investigator (Eva Kimby on 5 April 2017), Pfized had provided free prevenar and some economic support for monitoring to this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top